Stability of Recombinant Human Platelet-Derived Growth Factor-BB– Regenerated Periodontal Defects: Sixty-Month Clinical and Radiographic Observations

Introduction: The availability of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) plus β-tricalcium phosphate (β-TCP) for periodontal therapeutic use resulted from a large-scale, prospective, masked, randomized clinical trial. This pivotal trial indicated that this combination can safely and effectively be used to treat advanced periodontal osseous defects. Previous reports demonstrated significant gain in clinical attachment level, linear bone gain, and percentage bone fill after 6 months. Subsequent evaluation of selected cases 24 months after treatment indicated the clinical gains were maintainable. Furthermore, there appeared to be substantial increase in linear bone gain and percentage bone fill. Radiographically, there was increased radiopacity and bone trabeculation, suggesting bone maturation.Case Series: This report presents representative cases from the rhPDGF-BB plus β-TCP pivotal clinical trial after 60 months. Maximal regenerative results were achieved after 12 months and main...